4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
More News
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.66% and -94.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.